

Eugene Braunwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4058237/publications.pdf>

Version: 2024-02-01

401
papers

74,809
citations

1799

103
h-index

517

267
g-index

406
all docs

406
docs citations

406
times ranked

39554
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine, 1996, 335, 1001-1009. | 27.0 | 7,059 |
| 2 | Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2007, 357, 2001-2015. | 27.0 | 5,933 |
| 3 | Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine, 2004, 350, 1495-1504. | 27.0 | 4,527 |
| 4 | Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104. | 27.0 | 4,215 |
| 5 | Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, The, 2014, 383, 955-962. | 13.7 | 3,942 |
| 6 | Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397. | 27.0 | 3,337 |
| 7 | Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326. | 27.0 | 3,017 |
| 8 | Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19. | 27.0 | 1,681 |
| 9 | Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166. | 27.0 | 1,645 |
| 10 | Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800. | 27.0 | 1,585 |
| 11 | TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation, 2000, 102, 2031-2037. | 1.6 | 1,302 |
| 12 | Biomarkers in Heart Failure. New England Journal of Medicine, 2008, 358, 2148-2159. | 27.0 | 1,111 |
| 13 | Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289. | 7.4 | 974 |
| 14 | Aortic Stenosis. Circulation, 1968, 38, 61-7. | 1.6 | 910 |
| 15 | Angiotensinâ€“Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine, 2019, 380, 539-548. | 27.0 | 848 |
| 16 | Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413. | 27.0 | 841 |
| 17 | Hypertrophic Cardiomyopathy. Circulation Research, 2017, 121, 749-770. | 4.5 | 790 |
| 18 | Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227. | 27.0 | 780 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet</i> , The, 2009, 374, 989-997. | 13.7 | 650 |
| 20 | The war against heart failure: the Lancet lecture. <i>Lancet</i> , The, 2015, 385, 812-824. | 13.7 | 646 |
| 21 | Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 1-20. | 4.1 | 612 |
| 22 | Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1968, 37, 759-788. | 1.6 | 557 |
| 23 | Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure. <i>Circulation Research</i> , 1967, 21, 341-354. | 4.5 | 518 |
| 24 | Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500. | 7.4 | 457 |
| 25 | Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1775. | 7.4 | 448 |
| 26 | The Effects of Nitroglycerin and Amyl Nitrite on Arteriolar and Venous Tone in the Human Forearm. <i>Circulation</i> , 1965, 32, 755-766. | 1.6 | 443 |
| 27 | Augmentation of the Plasma Nor-Epinephrine Response to Exercise in Patients with Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1962, 267, 650-654. | 27.0 | 440 |
| 28 | Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. <i>Circulation</i> , 2001, 103, 2550-2554. | 1.6 | 440 |
| 29 | Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillationâ€“Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFâ€“TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2. | 2.7 | 439 |
| 30 | Studies on Starling's Law of the Heart. <i>Circulation</i> , 1961, 24, 633-642. | 1.6 | 429 |
| 31 | Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533. | 7.4 | 410 |
| 32 | STUDIES ON THE FIRST DERIVATIVE OF THE VENTRICULAR PRESSURE PULSE IN MAN. <i>Journal of Clinical Investigation</i> , 1962, 41, 80-91. | 8.2 | 379 |
| 33 | Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006. | 7.4 | 375 |
| 34 | Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients. <i>Circulation</i> , 1964, 29, SUPPL 4:3-119. | 1.6 | 365 |
| 35 | A Classification of Unstable Angina Revisited. <i>Circulation</i> , 2000, 102, 118-122. | 1.6 | 348 |
| 36 | Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet</i> , The, 2015, 385, 2288-2295. | 13.7 | 335 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Velocity of contraction as a determinant of myocardial oxygen consumption. American Journal of Physiology, 1965, 209, 919-927. | 5.0 | 331 |
| 38 | Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. JAMA - Journal of the American Medical Association, 2017, 317, 1958. | 7.4 | 329 |
| 39 | Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology, 2005, 46, 1411-1416. | 2.8 | 306 |
| 40 | Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. Circulation, 2018, 137, 1571-1582. | 1.6 | 304 |
| 41 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728. | 2.8 | 303 |
| 42 | Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter Inhibitors. Journal of the American College of Cardiology, 2020, 75, 422-434. | 2.8 | 302 |
| 43 | Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443. | 2.2 | 293 |
| 44 | The Study of Left Ventricular Function in Man by Increasing Resistance to Ventricular Ejection with Angiotensin. Circulation, 1964, 29, 739-749. | 1.6 | 292 |
| 45 | Contractile State of the Left Ventricle in Man. Circulation Research, 1968, 22, 451-463. | 4.5 | 281 |
| 46 | Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation, 2015, 132, 1224-1233. | 1.6 | 267 |
| 47 | Transseptal Left Heart Catheterization. Circulation, 1962, 25, 15-21. | 1.6 | 263 |
| 48 | Effects of Changing Heart Rate in Man by Electrical Stimulation of the Right Atrium. Circulation, 1965, 32, 549-558. | 1.6 | 256 |
| 49 | Relative Roles of the Sympathetic and Parasympathetic Nervous Systems in the Reflex Control of Heart Rate. Circulation Research, 1965, 16, 363-375. | 4.5 | 250 |
| 50 | Transseptal left atrial puncture. American Journal of Cardiology, 1959, 3, 653-655. | 1.6 | 244 |
| 51 | A Hemodynamic Technic for the Detection of Hypertrophic Subaortic Stenosis. Circulation, 1961, 23, 189-194. | 1.6 | 235 |
| 52 | Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation, 2016, 134, 24-36. | 1.6 | 234 |
| 53 | Assessment of Cardiac Contractility. Circulation, 1971, 44, 47-58. | 1.6 | 228 |
| 54 | Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis. Circulation, 1964, 29, 84-98. | 1.6 | 219 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | A new technic for left ventricular angiocardiology and transseptal left heart catheterization. American Journal of Cardiology, 1960, 6, 1062-1064. | 1.6 | 217 |
| 56 | Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . | 3.7 | 215 |
| 57 | Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2017, 40, 69-76. | 8.6 | 205 |
| 58 | Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950. | 6.1 | 199 |
| 59 | Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. Journal of the American College of Cardiology, 2018, 72, 1845-1855. | 2.8 | 190 |
| 60 | Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764. | 7.4 | 187 |
| 61 | Unstable Angina. Circulation, 2013, 127, 2452-2457. | 1.6 | 186 |
| 62 | Functional Aortic Stenosis. Circulation, 1959, 20, 181-189. | 1.6 | 181 |
| 63 | The Syndrome of Severe Mitral Regurgitation with Normal Left Atrial Pressure. Circulation, 1963, 27, 29-35. | 1.6 | 181 |
| 64 | Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740. | 2.8 | 179 |
| 65 | The Mechanism of the Intraventricular Pressure Gradient in Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1966, 34, 558-578. | 1.6 | 177 |
| 66 | Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European Heart Journal, 2014, 35, 1457-1465. | 2.2 | 174 |
| 67 | Atrial Failure as a Clinical Entity. Journal of the American College of Cardiology, 2020, 75, 222-232. | 2.8 | 174 |
| 68 | Left Ventricular Performance During Muscular Exercise in Patients with and without Cardiac Dysfunction. Circulation, 1966, 34, 597-608. | 1.6 | 172 |
| 69 | Impaired Rate of Left Ventricular Filling in Idiopathic Hypertrophic Subaortic Stenosis and Valvular Aortic Stenosis. Circulation, 1968, 37, 8-14. | 1.6 | 172 |
| 70 | Studies on Cardiac Dimensions in Intact Unanesthetized Man. Circulation, 1965, 32, 767-771. | 1.6 | 169 |
| 71 | Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643. | 13.7 | 167 |
| 72 | Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade. Circulation, 1967, 35, 847-851. | 1.6 | 165 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Left Atrial and Left Ventricular Pressures in Subjects without Cardiovascular Disease. <i>Circulation</i> , 1961, 24, 267-269. | 1.6 | 163 |
| 74 | Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2002, 106, 1312-1316. | 1.6 | 160 |
| 75 | Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921. | 2.8 | 157 |
| 76 | Acute Severe Mitral Regurgitation Secondary to Ruptured Chordae Tendineae. <i>Circulation</i> , 1966, 33, 58-70. | 1.6 | 153 |
| 77 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet</i> , The, 2015, 385, 2280-2287. | 13.7 | 153 |
| 78 | Partition of Blood Flow to the Cutaneous and Muscular Beds of the Forearm at Rest and during Leg Exercise in Normal Subjects and in Patients with Heart Failure. <i>Circulation Research</i> , 1969, 24, 799-806. | 4.5 | 152 |
| 79 | Diabetes, heart failure, and renal dysfunction: The vicious circles. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 298-302. | 3.1 | 151 |
| 80 | Characterization of the Circulatory Response to Maximal Upright Exercise in Normal Subjects and Patients with Heart Disease. <i>Circulation</i> , 1967, 35, 1049-1062. | 1.6 | 150 |
| 81 | Mechanism of Norepinephrine Depletion in Experimental Heart Failure Produced by Aortic Constriction in the Guinea Pig. <i>Circulation Research</i> , 1965, 17, 312-321. | 4.5 | 147 |
| 82 | Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2017, 2, 547. | 6.1 | 144 |
| 83 | Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313. | 1.6 | 143 |
| 84 | Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, . | 4.8 | 139 |
| 85 | Determination of Fraction of Left Ventricular Volume Ejected per Beat and of Ventricular End-Diastolic and Residual Volumes. <i>Circulation</i> , 1962, 25, 674-685. | 1.6 | 138 |
| 86 | Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142. | 2.2 | 138 |
| 87 | The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1029-1041. | 2.8 | 133 |
| 88 | Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178. | 2.8 | 133 |
| 89 | Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. <i>Journal of Clinical Investigation</i> , 1970, 49, 1007-1015. | 8.2 | 132 |
| 90 | The Circulatory Response of Patients with Idiopathic Hypertrophic Subaortic Stenosis to Nitroglycerin and to the Valsalva Maneuver. <i>Circulation</i> , 1964, 29, 422-431. | 1.6 | 131 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288. | 1.6 | 129 |
| 92 | Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1968, 37, 589-596. | 1.6 | 127 |
| 93 | Updates on Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 718. | 6.1 | 127 |
| 94 | Reduction of the Cardiac Response to Postganglionic Sympathetic Nerve Stimulation in Experimental Heart Failure. <i>Circulation Research</i> , 1966, 19, 51-56. | 4.5 | 126 |
| 95 | Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure. <i>Circulation Research</i> , 1967, 21, 365-374. | 4.5 | 124 |
| 96 | Electroaugmentation of Ventricular Performance and Oxygen Consumption by Repetitive Application of Paired Electrical Stimuli. <i>Circulation Research</i> , 1965, 16, 332-342. | 4.5 | 120 |
| 97 | Left Heart Catheterization by the Transseptal Route. <i>Circulation</i> , 1960, 22, 927-934. | 1.6 | 119 |
| 98 | Alterations in Regional Pulmonary Blood Flow in Mitral Valve Disease Studied by Radioisotope Scanning. <i>Circulation</i> , 1966, 34, 363-376. | 1.6 | 117 |
| 99 | Studies on Digitalis. <i>Circulation</i> , 1966, 34, 532-539. | 1.6 | 116 |
| 100 | Supravalvular Aortic Stenosis. <i>Circulation</i> , 1959, 20, 1003-1010. | 1.6 | 113 |
| 101 | Cliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022, 386, 2024-2034. | 27.0 | 113 |
| 102 | Prosthetic Replacement of the Mitral Valve. <i>Circulation</i> , 1967, 35, 962-979. | 1.6 | 112 |
| 103 | Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGEÂAF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382. | 2.8 | 111 |
| 104 | Studies on Digitalis. <i>Circulation</i> , 1962, 26, 166-173. | 1.6 | 108 |
| 105 | Determinants of atrial contractile force in the intact heart. <i>American Journal of Physiology</i> , 1965, 209, 1061-1068. | 5.0 | 108 |
| 106 | Platelet Inhibition With Ticagrelor 60ÂmgÂVersus 90 mg Twice Daily in theÂPEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154. | 2.8 | 108 |
| 107 | Association of Apolipoprotein Bâ€“Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. <i>JAMA Cardiology</i> , 2022, 7, 250. | 6.1 | 108 |
| 108 | Cardiomyopathies. <i>Circulation Research</i> , 2017, 121, 711-721. | 4.5 | 106 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Studies on Starling's Law of the Heart. <i>Circulation</i> , 1964, 30, 719-727. | 1.6 | 103 |
| 110 | Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 OrigBT /Overlook 10 Tf | 1.6 | 103 |
| 111 | Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771. | 1.6 | 99 |
| 112 | Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943. | 11.4 | 96 |
| 113 | Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107. | 4.1 | 95 |
| 114 | An Intrinsic Adrenergic Vasodilator Mechanism in the Coronary Vascular Bed of the Dog. <i>Circulation Research</i> , 1965, 16, 376-382. | 4.5 | 94 |
| 115 | Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577. | 1.6 | 94 |
| 116 | Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1. | 2.7 | 93 |
| 117 | Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 93 |
| 118 | Idiopathic myocardial hypertrophy without congestive heart failure or obstruction to blood flow. <i>American Journal of Medicine</i> , 1963, 35, 7-19. | 1.5 | 89 |
| 119 | Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5. | 2.7 | 89 |
| 120 | Studies on Starling's Law of the Heart. <i>Circulation Research</i> , 1960, 8, 1254-1263. | 4.5 | 88 |
| 121 | Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425. | 6.1 | 88 |
| 122 | Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550. | 2.2 | 88 |
| 123 | Left Atrial Pressure Pulse in Mitral Valve Disease. <i>Circulation</i> , 1957, 16, 399-405. | 1.6 | 87 |
| 124 | Augmented Sympathetic Neurotransmitter Activity in the Peripheral Vascular Bed of Patients with Congestive Heart Failure and Cardiac Norepinephrine Depletion. <i>Circulation</i> , 1968, 38, 629-634. | 1.6 | 87 |
| 125 | Mechanism of increase of myocardial oxygen uptake produced by catecholamines1. <i>American Journal of Physiology</i> , 1965, 209, 913-918. | 5.0 | 86 |
| 126 | Myocardial High Energy Phosphate Stores in Acutely Induced Hypoxic Heart Failure. <i>Circulation Research</i> , 1966, 19, 221-229. | 4.5 | 83 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082. | 2.0 | 83 |
| 128 | Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846. | 6.1 | 81 |
| 129 | Study of the Relationship Between the Neurotransmitter Store and Adrenergic Nerve Block Induced by Reserpine and Guanethidine. <i>Circulation Research</i> , 1963, 12, 264-268. | 4.5 | 80 |
| 130 | Circulatory Effects of Electrical Stimulation of the Carotid Sinus Nerves in Man. <i>Circulation</i> , 1969, 40, 269-276. | 1.6 | 79 |
| 131 | A Method for the Detection and Quantification of Impaired Sodium Excretion. <i>Circulation</i> , 1965, 32, 223-231. | 1.6 | 78 |
| 132 | Study design and rationale for the Stabilization of pLaques using Darapladibâ€”Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1. | 2.7 | 77 |
| 133 | Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17. | 6.1 | 77 |
| 134 | Circulatory Effects of Acute Expansion of Blood Volume:. <i>Circulation Research</i> , 1966, 19, 26-32. | 4.5 | 75 |
| 135 | Epilogue: What Do Clinicians Expect From Imagers?. <i>Journal of the American College of Cardiology</i> , 2006, 47, C101-C103. | 2.8 | 74 |
| 136 | Efficacy and Safety of Ticagrelor OverÂTime in Patients With Prior MI inÂPEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375. | 2.8 | 74 |
| 137 | Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153. | 8.6 | 73 |
| 138 | Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <scp>ENGAGE AFâ€”TIMI</scp> 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161. | 7.1 | 73 |
| 139 | Left Heart Catheterization by the Transbronchial Route. <i>Circulation</i> , 1957, 16, 1033-1039. | 1.6 | 71 |
| 140 | The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016, 37, 3576-3584. | 2.2 | 71 |
| 141 | Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€”MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048. | 7.1 | 70 |
| 142 | Editorial. <i>Circulation</i> , 1962, 26, 161-165. | 1.6 | 67 |
| 143 | Cell-Based Therapy in Cardiac Regeneration. <i>Circulation Research</i> , 2018, 123, 132-137. | 4.5 | 67 |
| 144 | Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527. | 2.2 | 67 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Unstable Angina and Non-ST Elevation Myocardial Infarction. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 924-932. | 5.6 | 66 |
| 146 | Physiological Differences between the Effects of Neuronally Released and Bloodborne Norepinephrine on Beta Adrenergic Receptors in the Arterial Bed of the Dog. Circulation Research, 1967, 21, 217-228. | 4.5 | 65 |
| 147 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117. | 2.2 | 65 |
| 148 | Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American College of Cardiology, 2020, 75, 435-447. | 2.8 | 65 |
| 149 | Studies on Digitalis. Circulation, 1961, 23, 376-382. | 1.6 | 64 |
| 150 | Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 999. | 6.1 | 64 |
| 151 | Soluble ST2 in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, . | 3.7 | 64 |
| 152 | Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation, 2015, 132, e121-2. | 1.6 | 61 |
| 153 | Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide (NT-pro-BNP) in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal, 2018, 198, 145-151. | 2.7 | 60 |
| 154 | The rise of cardiovascular medicine. European Heart Journal, 2012, 33, 838-845. | 2.2 | 59 |
| 155 | Research Advances in Heart Failure. Circulation Research, 2013, 113, 633-645. | 4.5 | 59 |
| 156 | Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. JAMA - Journal of the American Medical Association, 2014, 312, 789. | 7.4 | 58 |
| 157 | Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. American Journal of Medicine, 2016, 129, 850-857.e2. | 1.5 | 58 |
| 158 | A Method for the Detection and Estimation of Aortic Regurgitant Flow in Man. Circulation, 1958, 17, 505-511. | 1.6 | 57 |
| 159 | Congenital Aortopulmonary Septal Defect. Circulation, 1962, 25, 463-476. | 1.6 | 57 |
| 160 | Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology, 2020, 5, 202. | 6.1 | 57 |
| 161 | Influence of Carotid Baroreceptors and Vasoactive Drugs on Systemic Vascular Volume and Venous Distensibility. Circulation Research, 1961, 9, 75-82. | 4.5 | 56 |
| 162 | Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496. | 2.8 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | The treatment of acute myocardial infarction: the Past, the Present, and the Future. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 9-12. | 1.0 | 55 |
| 164 | Outcomes of Women Compared With Men After Non-“ST-Segment Elevation Acute”Coronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022. | 2.8 | 54 |
| 165 | Interatrial Communication and Left Atrial Hypertension. Circulation, 1963, 28, 853-860. | 1.6 | 53 |
| 166 | Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, . | 3.7 | 53 |
| 167 | Hemodynamic-Phonocardiographic Correlations of the Fourth Heart Sound in Aortic Stenosis. Circulation, 1962, 26, 92-98. | 1.6 | 52 |
| 168 | Studies on the Function of the Adrenergic Nerve Endings in the Heart. Circulation, 1963, 28, 958-969. | 1.6 | 52 |
| 169 | The Incidence and Management of "Medical" Complications Following Cardiac Operations. Circulation, 1965, 32, 608-619. | 1.6 | 52 |
| 170 | Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation, 2003, 108, 28III-37. | 1.6 | 52 |
| 171 | Idiopathic Hypertrophic Subaortic Stenosis: II. Operative Treatment and the Results of Pre- and Postoperative Hemodynamic Evaluations. Circulation, 1964, 29, . | 1.6 | 52 |
| 172 | The Nitrous Oxide Test. Circulation, 1958, 17, 284-291. | 1.6 | 51 |
| 173 | Potent P2Y ₁₂ Inhibitors in Men Versus Women. Journal of the American College of Cardiology, 2017, 69, 1549-1559. | 2.8 | 51 |
| 174 | Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1818-1824. | 30.7 | 51 |
| 175 | The Effects of Surgical Abolition of Left-to-Right Shunts on the Pulmonary Vascular Dynamics of Patients with Pulmonary Hypertension. Circulation, 1962, 26, 1270-1278. | 1.6 | 50 |
| 176 | Studies on Cardiac Dimensions in Intact, Unanesthetized Man. Circulation, 1964, 29, 186-194. | 1.6 | 49 |
| 177 | Cardiology: the past, the present, and the future. Journal of the American College of Cardiology, 2003, 42, 2031-2041. | 2.8 | 49 |
| 178 | Galectin-3 in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2015, 3, 245-252. | 4.1 | 49 |
| 179 | Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268. | 2.2 | 49 |
| 180 | Significance of an Atrial Gallop Sound in Mitral Regurgitation. Circulation, 1967, 35, 112-118. | 1.6 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationâ€. European Heart Journal, 2015, 36, 1470-1477. | 2.2 | 47 |
| 182 | INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 3.9 | 47 |
| 183 | Congenital Aortic Stenosis. Circulation, 1958, 18, 1091-1104. | 1.6 | 46 |
| 184 | Interactions between Changes in the Intensity and Duration of the Active State in the Characterization of Inotropic Stimuli on Heart Muscle. Circulation Research, 1967, 21, 857-868. | 4.5 | 46 |
| 185 | Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378. | 2.0 | 46 |
| 186 | Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Europace, 2015, 17, 32-37. | 1.7 | 46 |
| 187 | Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2020, 5, 1236. | 6.1 | 46 |
| 188 | Effects of Acute Valvular Regurgitation on the Oxygen Consumption of the Canine Heart. Circulation Research, 1968, 23, 33-43. | 4.5 | 45 |
| 189 | Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 604-612. | 2.9 | 45 |
| 190 | Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2017, 10, e003878. | 3.9 | 45 |
| 191 | SGLT2 inhibitors: the statins of the 21st century. European Heart Journal, 2022, 43, 1029-1030. | 2.2 | 45 |
| 192 | Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure, 2019, 21, 1571-1579. | 7.1 | 44 |
| 193 | Assessment of Left Ventricular Performance in Man. Circulation, 1973, 47, 924-935. | 1.6 | 42 |
| 194 | Coronary Stent Thrombosis With Vorapaxar Versus Placebo. Journal of the American College of Cardiology, 2014, 64, 2309-2317. | 2.8 | 41 |
| 195 | GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 673-679. | 3.9 | 41 |
| 196 | The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. American Heart Journal, 2017, 187, 145-155. | 2.7 | 41 |
| 197 | Morning Resistance to Thrombolytic Therapy. Circulation, 1995, 91, 1604-1606. | 1.6 | 41 |
| 198 | Diagnostic Value of the First and Second Derivatives of the Arterial Pressure Pulse in Aortic Valve Disease and in Hypertrophic Subaortic Stenosis. Circulation, 1964, 30, 90-100. | 1.6 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 906-919. | 2.8 | 40 |
| 200 | Resting Ventricular Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 580-589. | 3.9 | 40 |
| 201 | Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. JACC: Heart Failure, 2016, 4, 923-931. | 4.1 | 40 |
| 202 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Circulation, 2016, 134, 861-871. | 1.6 | 40 |
| 203 | Aortic Stenosis. Circulation, 2018, 137, 2099-2100. | 1.6 | 40 |
| 204 | Studies on Starling's Law of the Heart. Circulation, 1962, 26, 516-524. | 1.6 | 39 |
| 205 | Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. Journal of the American College of Cardiology, 2013, 62, 242-251. | 2.8 | 39 |
| 206 | Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584. | 2.8 | 39 |
| 207 | Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. Circulation, 2015, 132, 1871-1879. | 1.6 | 39 |
| 208 | The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabolism, 2019, 30, 847-849. | 16.2 | 39 |
| 209 | Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799. | 4.1 | 39 |
| 210 | Causes of late mortality with dual antiplatelet therapy after coronary stents. European Heart Journal, 2015, 37, ehv614. | 2.2 | 38 |
| 211 | Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, . | 3.9 | 38 |
| 212 | Relationships Between the Release and Tissue Depletion of Norepinephrine from the Heart by Guanethidine and Reserpine. Circulation Research, 1963, 12, 256-263. | 4.5 | 37 |
| 213 | A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European Heart Journal, 2017, 38, ehv565. | 2.2 | 37 |
| 214 | Detection of Pulmonic and Tricuspid Valvular Regurgitation by Means of Indicator Solutions. Circulation, 1959, 20, 561-568. | 1.6 | 36 |
| 215 | Managing Stable Ischemic Heart Disease. New England Journal of Medicine, 2020, 382, 1468-1470. | 27.0 | 36 |
| 216 | Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2016, 1, 7. | 6.1 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8. | 1.5 | 34 |
| 218 | Induced Septal Infarction. Circulation, 1997, 95, 1981-1982. | 1.6 | 34 |
| 219 | Pulsus Alternans in Aortic Stenosis. Circulation, 1958, 18, 64-70. | 1.6 | 33 |
| 220 | The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. Clinical Cardiology, 2008, 31, 117-120. | 1.8 | 33 |
| 221 | Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 473. | 6.1 | 33 |
| 222 | Gastrointestinal Bleeding With Edoxaban Versus Warfarin. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003998. | 2.2 | 33 |
| 223 | Intracardiac Injection of Radioactive Krypton. Circulation, 1960, 21, 1126-1133. | 1.6 | 32 |
| 224 | Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. Journal of Thrombosis and Thrombolysis, 1996, 3, 117-125. | 2.1 | 32 |
| 225 | Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal of Cardiac Failure, 2018, 24, 255-265. | 1.7 | 32 |
| 226 | Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation, 2018, 138, 1963-1973. | 1.6 | 32 |
| 227 | Angiotensin Receptor-Nephrilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology, 2020, 76, 1034-1048. | 2.8 | 32 |
| 228 | Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478. | 1.6 | 32 |
| 229 | Origin of Heart Sounds as Elucidated by Analysis of the Sequence of Cardiodynamic Events. Circulation, 1958, 18, 971-974. | 1.6 | 30 |
| 230 | Effects of Frequency of Contraction and Ionic Environment on the Responses of Heart Muscle to Acetylcholine. Circulation Research, 1967, 21, 573-582. | 4.5 | 30 |
| 231 | Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure, 2016, 4, 726-735. | 4.1 | 30 |
| 232 | Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, . | 3.7 | 30 |
| 233 | Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2018, 320, 1751. | 7.4 | 30 |
| 234 | Uptake and Metabolism of Tritiated Norepinephrine in the Isolated Canine Heart. Circulation Research, 1963, 12, 220-227. | 4.5 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2016, 29, 537-544. | 2.8 | 29 |
| 236 | Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 1197-1207. | 2.8 | 29 |
| 237 | The Management of Heart Failure. Circulation: Heart Failure, 2008, 1, 58-62. | 3.9 | 28 |
| 238 | Modes and timing of death in 66,252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820. | 2.2 | 28 |
| 239 | Severe Mitral Regurgitation Following Acute Myocardial Infarction and Ruptured Papillary Muscle. Circulation, 1968, 37, . | 1.6 | 28 |
| 240 | Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89. | 1.6 | 28 |
| 241 | Analysis of the Acute Circulatory Effects of Guanethidine and Bretylium. Circulation Research, 1962, 10, 83-88. | 4.5 | 27 |
| 242 | Circulatory response to hypoxia in unanesthetized dogs with and without cardiac denervation. American Journal of Physiology, 1964, 207, 753-758. | 5.0 | 27 |
| 243 | Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632. | 2.2 | 27 |
| 244 | Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255. | 6.1 | 27 |
| 245 | Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circulation: Heart Failure, 2021, 14, e007034. | 3.9 | 27 |
| 246 | Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2021, 42, 1698-1706. | 2.2 | 27 |
| 247 | A Simplified Indicator-Dilution Technic for the Localization of Left-to-Right Circulatory Shunts. Circulation, 1959, 20, 875-880. | 1.6 | 26 |
| 248 | Effects of Changes in Body Position on the Severity of Obstruction to Left Ventricular Outflow in Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1966, 33, 374-382. | 1.6 | 26 |
| 249 | CLINICAL AND HEMODYNAMIC APPRAISAL OF BETA ADRENERGIC BLOCKING DRUGS. Annals of the New York Academy of Sciences, 1967, 139, 952-967. | 3.8 | 26 |
| 250 | Effects of Chronic Heart Failure on the Inotropic Response of the Right Ventricle of the Conscious Dog to a Cardiac Glycoside and to Tachycardia. Circulation, 1974, 50, 728-734. | 1.6 | 26 |
| 251 | Assessing the Current Role of Platelet Function Testing. Clinical Cardiology, 2008, 31, I10-I16. | 1.8 | 26 |
| 252 | Cardiovascular science: opportunities for translating research into improved care. Journal of Clinical Investigation, 2013, 123, 6-10. | 8.2 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Effects of Reserpine and Guanethidine on Venous Reflexes. Circulation Research, 1962, 11, 889-894. | 4.5 | 25 |
| 254 | Editorial. Circulation, 1965, 32, 677-681. | 1.6 | 25 |
| 255 | Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 856-864. | 2.9 | 25 |
| 256 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206. | 3.0 | 25 |
| 257 | Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). American Journal of Cardiology, 2019, 123, 145-152. | 1.6 | 25 |
| 258 | Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure, 2020, 26, 371-380. | 1.7 | 25 |
| 259 | Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 1095-1106. | 2.8 | 25 |
| 260 | Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2020, 304, 185-191. | 1.7 | 25 |
| 261 | The Effects of Mitral Regurgitation on the Pattern of Instantaneous Aortic Blood Flow Clinical and Experimental Observations. Circulation, 1967, 36, 45-53. | 1.6 | 24 |
| 262 | Integrity of Energy Stores in Cat Papillary Muscle. Circulation Research, 1968, 22, 213-219. | 4.5 | 24 |
| 263 | JACC: Cardiovascular Interventions: The End of the Beginning. JACC: Cardiovascular Interventions, 2008, 1, 1-2. | 2.9 | 24 |
| 264 | Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041. | 2.2 | 23 |
| 265 | Thrombolysis In Myocardial Infarction (TIMI) Study Group. Journal of the American College of Cardiology, 2021, 77, 2822-2845. | 2.8 | 23 |
| 266 | Adventures in Cardiovascular Research. Circulation, 2009, 120, 170-180. | 1.6 | 22 |
| 267 | Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692. | 1.6 | 22 |
| 268 | Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation, 2019, 140, 1792-1801. | 1.6 | 22 |
| 269 | Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149. | 3.4 | 22 |
| 270 | Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695. | 1.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 271 | Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1499-1507. | 2.8 | 22 |
| 272 | Precordial Scanning. <i>Circulation</i> , 1961, 23, 21-29. | 1.6 | 21 |
| 273 | D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018, 122, 1459-1464. | 1.6 | 21 |
| 274 | Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 830-838. | 1.8 | 20 |
| 275 | How to live to 100 before developing clinical coronary artery disease: a suggestion. <i>European Heart Journal</i> , 2022, 43, 249-250. | 2.2 | 20 |
| 276 | Prognosis in the Thrombolysis in Myocardial Ischemia III Registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , 2002, 90, 821-826. | 1.6 | 19 |
| 277 | Clinical Efforts to Reduce Myocardial Infarct Size—The Next Step. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 349-353. | 2.0 | 19 |
| 278 | High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 ^Â P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315. | 3.2 | 19 |
| 279 | Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843. | 4.1 | 19 |
| 280 | Mechanochemistry of Cardiac Muscle. <i>Circulation Research</i> , 1969, 24, 313-320. | 4.5 | 18 |
| 281 | An Important Step for Thrombocardiology. <i>New England Journal of Medicine</i> , 2017, 377, 1387-1388. | 27.0 | 18 |
| 282 | Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018, 257, 102-107. | 1.7 | 18 |
| 283 | Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008. | 3.4 | 18 |
| 284 | Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF—TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 176-185. | 1.0 | 18 |
| 285 | Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902. | 1.8 | 18 |
| 286 | Starling's law of the heart. VII: Ventricular function in closed-chest unanesthetized dogs. <i>American Journal of Physiology</i> , 1963, 204, 439-445. | 5.0 | 17 |
| 287 | Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 431-440. | 1.0 | 17 |
| 288 | Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored — Until Now. <i>American Journal of Medicine</i> , 2017, 130, 119-123. | 1.5 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 289 | Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). American Journal of Cardiology, 2018, 122, 1896-1901. | 1.6 | 17 |
| 290 | Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008. | 3.7 | 17 |
| 291 | Treatment of Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2284-2285. | 27.0 | 16 |
| 292 | Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension, 2019, 74, 597-605. | 2.7 | 16 |
| 293 | Hypertrophic Cardiomyopathy: The Early Years. Journal of Cardiovascular Translational Research, 2009, 2, 341-348. | 2.4 | 15 |
| 294 | The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 762-770. | 0.8 | 14 |
| 295 | Responsiveness to loop diuretics in heart failure. European Heart Journal, 2014, 35, 1235-1237. | 2.2 | 14 |
| 296 | The Year in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 201-214. | 2.8 | 14 |
| 297 | Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. JAMA Network Open, 2020, 3, e1921669. | 5.9 | 14 |
| 298 | Protection of the Ischemic Myocardium. Hospital Practice (1995), 1973, 8, 61-74. | 1.0 | 13 |
| 299 | The ten advances that have defined modern cardiology. Trends in Cardiovascular Medicine, 2014, 24, 179-183. | 4.9 | 13 |
| 300 | Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2Â°P)â€“TIMI 50. Journal of the American Heart Association, 2016, 5, . | 3.7 | 13 |
| 301 | Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillationâ€“Thrombolysis in Myocardial Infarction 48 (ENGAGE AFâ€“TIMI 48) trial. American Heart Journal. 2016. 172. 144-151. | 2.7 | 13 |
| 302 | Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58Â634 patients across four randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f40-f49. | 3.0 | 13 |
| 303 | A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581. | 8.6 | 13 |
| 304 | Heart failure with preserved ejection fraction: a stepchild no more!. European Heart Journal, 2021, 42, 3900-3901. | 2.2 | 13 |
| 305 | Chapter 4: Deaths Related to Cardiac Catheterization. Circulation, 1968, 37, . | 1.6 | 13 |
| 306 | A Simplified Technic for the Detection of Patent Ductus Arteriosus and of Other Left-to-Right Shunts Originating from the Aorta. Circulation, 1961, 23, 279-285. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 307 | Hypertrophic Cardiomyopathy – The Benefits of a Multidisciplinary Approach. New England Journal of Medicine, 2002, 347, 1306-1307. | 27.0 | 12 |
| 308 | Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care, 2016, 39, 1329-1337. | 8.6 | 12 |
| 309 | Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 129-136. | 2.8 | 12 |
| 310 | Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 186-193. | 1.0 | 12 |
| 311 | Effects of Aortic Regurgitation on Left Ventricular Performance. Circulation, 1965, 31, . | 1.6 | 12 |
| 312 | Combined Prosthetic Replacement of the Mitral and Aortic Valves. Circulation, 1967, 35, 115-23. | 1.6 | 12 |
| 313 | Circulatory effects of profound hypothermia during extracorporeal circulation. American Journal of Physiology, 1962, 202, 523-526. | 5.0 | 11 |
| 314 | The Assessment of Operative Results in Congenital Heart Disease by Intraoperative Indicator-Dilution Curves. Circulation, 1966, 33, 263-269. | 1.6 | 11 |
| 315 | Preface. Heart Failure Clinics, 2009, 5, xiii-xiv. | 2.1 | 11 |
| 316 | Another step toward personalized care of patients with heart failure. European Journal of Heart Failure, 2015, 17, 988-990. | 7.1 | 11 |
| 317 | The Evidence Supporting Cardiovascular Guidelines. JAMA - Journal of the American Medical Association, 2019, 321, 1053. | 7.4 | 11 |
| 318 | Angiotensin-Neprilysin Inhibition in Black Americans. JACC: Heart Failure, 2020, 8, 859-866. | 4.1 | 11 |
| 319 | Angiographic Outcomes With Early Eptifibatide Therapy in Non-“ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). American Journal of Cardiology, 2014, 113, 1297-1305. | 1.6 | 10 |
| 320 | Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 1466-1475. | 2.8 | 10 |
| 321 | Baseline Characteristics of the VANISH Cohort. Circulation: Heart Failure, 2019, 12, e006231. | 3.9 | 10 |
| 322 | Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation, 2021, 143, 673-684. | 1.6 | 10 |
| 323 | Cholesterol: the race to the bottom. European Heart Journal, 2021, 42, 4612-4613. | 2.2 | 10 |
| 324 | Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. Clinical Cardiology, 2008, 31, 12-19. | 1.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2008, 52, 1095-1103. | 2.8 | 9 |
| 326 | Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2001, 53, 6-11. | 1.7 | 8 |
| 327 | Progress in the Noninvasive Detection of High-Risk Coronary Plaques—. Journal of the American College of Cardiology, 2015, 66, 347-349. | 2.8 | 8 |
| 328 | Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 164-172. | 1.0 | 8 |
| 329 | Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using DarapladibThrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. Journal of the American Heart Association, 2017, 6, . | 3.7 | 8 |
| 330 | Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . | 2.2 | 8 |
| 331 | Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Journal of the American Heart Association, 2018, 7, e009260. | 3.7 | 8 |
| 332 | Cardiac cell therapy: a call for action. European Heart Journal, 2022, 43, 2352-2353. | 2.2 | 8 |
| 333 | EFFECTS OF HEART FAILURE, VENTRICULAR HYPERTROPHY, AND ALTERATIONS IN THE THYROID STATE ON THE CONTRACTILITY OF ISOLATED CARDIAC MUSCLE. Annals of the New York Academy of Sciences, 1969, 156, 379-386. | 3.8 | 7 |
| 334 | Results of the Treat Angina With Aggrastat and Determine the Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI 18) Trial: A Comparison of Invasive Versus Conservative Strategy in Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. Circulation, 2000, 102, 2672-2672. | 1.6 | 7 |
| 335 | Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. Clinical Cardiology, 2008, 31, 121-127. | 1.8 | 7 |
| 336 | Antiplatelet Therapy and Platelet Function Testing. Clinical Cardiology, 2008, 31, 136-136. | 1.8 | 7 |
| 337 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2011, 58, 2342-2354. | 2.8 | 7 |
| 338 | Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. Cardiac Failure Review, 2019, 5, 27-30. | 3.0 | 7 |
| 339 | Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). American Journal of Cardiology, 2020, 125, 661-669. | 1.6 | 7 |
| 340 | Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396. | 4.0 | 7 |
| 341 | Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446. | 3.7 | 7 |
| 342 | Chapter 17: Transseptal Left Heart Catheterization. Circulation, 1968, 37, . | 1.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Effect of hemorrhagic shock on release of norepinephrine by tyramine. American Journal of Physiology, 1964, 206, 1262-1266. | 5.0 | 6 |
| 344 | Hypertrophic cardiomyopathy: The first century 1869â€“1969. Global Cardiology Science & Practice, 2012, 2012, 5. | 0.4 | 6 |
| 345 | Circulation : The Beat Goes On. Circulation, 2016, 134, 6-8. | 1.6 | 6 |
| 346 | Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace, 2019, 21, 306-312. | 1.7 | 6 |
| 347 | Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AFâ€“TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006511. | 2.2 | 6 |
| 348 | Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006. | 3.6 | 6 |
| 349 | Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32. | 2.7 | 6 |
| 350 | Tissue plasminogen activator and acute pulmonary embolism. Journal of Cellular Biochemistry, 1988, 38, 303-312. | 2.6 | 5 |
| 351 | The Year in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 386-395. | 2.8 | 5 |
| 352 | Cardiovascular pharmacology: a look back and a glimpse into the future. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 7-9. | 3.0 | 5 |
| 353 | Reduction of LDL-cholesterol: important at all ages. European Heart Journal, 2016, 37, 1982-1984. | 2.2 | 5 |
| 354 | Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2Â°P-TIMI 50). American Journal of Cardiology, 2016, 117, 1055-1058. | 1.6 | 5 |
| 355 | Cardiology in 2021. European Heart Journal, 2021, 42, 959-959. | 2.2 | 5 |
| 356 | Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Journal of Clinical Neuroscience, 2021, 86, 294-300. | 1.5 | 5 |
| 357 | Chapter 18: Percutaneous Left Ventricular Puncture. Circulation, 1968, 37, . | 1.6 | 5 |
| 358 | Cardiology: how did we get here, where are we today and where are we going?. Canadian Journal of Cardiology, 2005, 21, 1015-7. | 1.7 | 5 |
| 359 | Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706. | 3.0 | 5 |
| 360 | Use of Krypton ⁸⁵ for the Measurement of Cardiac Output by the Single-Injection Indicator-Dilution Technique. Circulation Research, 1961, 9, 984-988. | 4.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Changing the practice of cardiovascular medicine. <i>Atherosclerosis Supplements</i> , 2001, 2, 27-30. | 1.2 | 4 |
| 362 | Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: Table A1. <i>European Heart Journal</i> , 2016, 37, 745-746. | 2.2 | 4 |
| 363 | Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. <i>Journal of the American Heart Association</i> , 2022, 11, e022733. | 3.7 | 4 |
| 364 | Control of residual dyslipidaemic risk. <i>European Heart Journal</i> , 0, , . | 2.2 | 4 |
| 365 | Ligation of the Main Pulmonary Artery and Systemic-Pulmonary Arterial Anastomosis. <i>Circulation</i> , 1966, 34, 55-60. | 1.6 | 3 |
| 366 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1386-1395. | 2.8 | 3 |
| 367 | Intravenous Beta-Blockade for Limiting Myocardial Infarct Size. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2105-2107. | 2.8 | 3 |
| 368 | Reflections on Hypertrophic Cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 2969-2970. | 2.2 | 3 |
| 369 | A tribute to Attilio Maseri. <i>European Heart Journal</i> , 2021, 42, 4410-4412. | 2.2 | 3 |
| 370 | Heart failure: a 70 year Odyssey. <i>European Heart Journal</i> , 2022, 43, 1697-1699. | 2.2 | 3 |
| 371 | Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, I28-I35. | 1.8 | 2 |
| 372 | Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, I1-I11. | 1.8 | 2 |
| 373 | HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073. | 3.2 | 2 |
| 374 | Fondation Leducq. <i>Circulation Research</i> , 2014, 115, 419-422. | 4.5 | 2 |
| 375 | Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. <i>American Journal of Medicine</i> , 2017, 130, 1236-1237. | 1.5 | 2 |
| 376 | Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458. | 1.6 | 2 |
| 377 | The path to universality. <i>European Journal of Heart Failure</i> , 2021, 23, 381-383. | 7.1 | 2 |
| 378 | The Birth of Cardiology: The Golden Decade. <i>European Heart Journal</i> , 2021, 42, 1650-1651. | 2.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 379 | The war on heart failure. European Journal of Heart Failure, 2021, 23, 915-916. | 7.1 | 2 |
| 380 | The American Society for Clinical Investigation, 1952â€“1975: a personal perspective. Journal of Clinical Investigation, 2008, 118, 1228-1230. | 8.2 | 2 |
| 381 | Changing the Trajectory of Heart Failure and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.00470122. | 4.5 | 2 |
| 382 | Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. Anesthesiology, 2007, 107, 161-163. | 2.5 | 1 |
| 383 | Response to Letter Regarding Article, “Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38” Circulation. 2010. 122, . | 1.6 | 1 |
| 384 | CardioPulse Articles. European Heart Journal, 2013, 34, 943-948. | 2.2 | 1 |
| 385 | In Memoriam”John Ross Jr, MD. JAMA Cardiology, 2019, 4, 967. | 6.1 | 1 |
| 386 | A new initiative of the European Heart Journal: the Desmond Julian Award. European Heart Journal, 2021, 42, 3894-3895. | 2.2 | 1 |
| 387 | The Haemodynamic Effects of Circulatory Drugs in Patients with Idiopathic Hypertrophic Subaortic Stenosis. Novartis Foundation Symposium, 0, , 172-188. | 1.1 | 1 |
| 388 | Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?. European Heart Journal, 0, , . | 2.2 | 1 |
| 389 | Fraud and other matters?. Nature, 1987, 328, 196-196. | 27.8 | 0 |
| 390 | Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. Journal of Thrombosis and Thrombolysis, 1997, 4, 321-323. | 2.1 | 0 |
| 391 | Summary of Issues Emanating from the Workshop on Congestive Heart Failure. Artificial Organs, 2008, 6, 342-344. | 1.9 | 0 |
| 392 | Burton E. Sobel: 1937â€“2013. Circulation, 2013, 128, 188-189. | 1.6 | 0 |
| 393 | Response to Letter Regarding Article, “Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT” Circulation, 2016, 133, e463. | 1.6 | 0 |
| 394 | Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes”Reply. JAMA Cardiology, 2017, 2, 821. | 6.1 | 0 |
| 395 | Andr   Cournand, Bellevue    s Cardiopulmonary Laboratory, and Research on Heart Failure. Annals of the American Thoracic Society, 2018, 15, S12-S14. | 3.2 | 0 |
| 396 | Response by Bohula et al to Letters Regarding Article, “Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq0 0 0 rgBTdOverlook 10 Tf 50 | | |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Transseptal left heart catheterization: birth, death, and resurrection. <i>European Heart Journal</i> , 2021, 42, 2327-2328. | 2.2 | 0 |
| 398 | Age and Routine Invasive Management of Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2004, 141, 967. | 3.9 | 0 |
| 399 | Chapter 13: Severe Hypotension. <i>Circulation</i> , 1968, 37, . | 1.6 | 0 |
| 400 | Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis: Surgical Methods and the Results of Operation. <i>Novartis Foundation Symposium</i> , 0, , 250-265. | 1.1 | 0 |
| 401 | Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?â€”Reply. <i>JAMA Cardiology</i> , 2022, , . | 6.1 | 0 |